Japan’s Ministry of Health, Labour, and Welfare has approved Abecma (idecabtagene vicleucel) as its first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma who received at least three prior therapies. This includes patients treated at least with one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one CD38 inhibitor, and whose disease failed to respond or relapsed after their last therapy. In Japan, no other treatment is approved for this group of patients. “Abecma delivers…
You must be logged in to read/download the full post.
The post Japan OKs Abecma as 1st CAR T-cell for Heavily Treated Myeloma appeared first on BioNewsFeeds.